Tailwinds’ Take: the licensing and partnering strategy at biOasis appeared to be on hold for a while as their new CEO settled into his role. This hire would seem to kick start this program. It remains to be seen what the Company intends to do in terms of licensing, but we now know that they will be seeking partners and we should expect some positive announcements about this in the future.
VANCOUVER, BC, BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) welcomes Doug Williams, MBA, as executive vice president, chief business officer, effective immediately. Williams will report to Dr. Mark Day, president and chief executive officer of biOasis. In this newly created position, Williams will provide leadership and execute on the corporate development strategy that will maximize benefits for strategic partners and shareholders. Williams will be responsible for leading corporate and business development, as well as the alliance management efforts at biOasis.
“We are delighted to welcome Doug Williams to our senior management team at biOasis. I know he will bring value as a business development leader and well-respected and strategic alliance professional,” said Dr. Day. “Doug will play a critical role in advancing our partnering strategy and create value through the prosecution of licensing opportunities for our proprietary blood-brain barrier drug delivery platform.”
Williams has more than 20 years of experience in the pharmaceutical and healthcare industries and has successfully led cross-functional, global alliances teams across multiple organizations. His alliance and partnering experience includes a broad set of partners including large, multinational pharmaceutical companies, as well as start-up biotechnology companies, which included global alliances with Shionogi, Exicure, AbbVie, Mylan and Takeda, among others.
Williams has been recognized as an industry leader who has presented, participated as a panelist, and moderated multiple industry partnering programs at industry events.
“Doug has a broad set of experiences having worked in leadership roles at healthcare technology startups, pharmaceutical and biotechnology companies. His diverse experience base will help propel our global partnering efforts,” said Rob Hutchison, founder and chairman of the board of directors. “Doug will be a great addition to the biOasis leadership team.”
Williams most recently came from Purdue Pharma L.P where he worked on strategic alliances and business development projects related to clinical and pre-clinical programs. Prior to Purdue, Williams built his own successful consulting business working with start-up healthcare technology companies.
Doug’s experience includes commercial sales, sales management, alliance management and business development. He has also held various positions of increasing responsibility at Pfizer, Johnson & Johnson, Elan, Sepracor and Kadmon over his 20 year career.
“I am eager to work with Mark on shaping the business strategy for biOasis as we continue to advance our proprietary blood-brain barrier technology platform,” said Williams. “I want to thank Rob and Mark for this opportunity. I look forward to sharing the biOasis story with new potential collaborators and leading the licensing and partnering efforts on behalf of the company and our shareholders.”
biOasis Technologies Inc. is a biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The delivery of therapeutics across the BBB represents the single greatest challenge in treating neurological disorders. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system diseases and disorders. The company maintains headquarters in Vancouver, Canada with offices in Connecticut, United States. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company please visit www.bioasis.ca.
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forwardlooking statements and information to reflect subsequent events or circumstances, except as required by law.
On Behalf of the Board of Directors
Dr. Mark Day, President and Chief Executive OfficerTailwinds' Disclaimers & Disclosures: For a full list of disclaimers and disclosures, please visit http://